Author(s):
Vinayaka Anuhya, Amberkar Mohanbabu Vittalrao, Meena Kumari Kamalkishore*, Brij Mohan Kumar Singh, Gangaparameswari Soundarrajan
Email(s):
meena.kumari@manipal.edu
DOI:
10.52711/0974-360X.2024.00362 
Address:
Vinayaka Anuhya1, Amberkar Mohanbabu Vittalrao2, Meena Kumari Kamalkishore3*, Brij Mohan Kumar Singh4, Gangaparameswari Soundarrajan1
1Postgraduate, Department of Pharmacology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Karnataka, Manipal, 576104, India.
2Professor, Department of Pharmacology, The Oxford Medical College, Hospital and Research Centre, Bangalore, Karnataka, India.
3Associate Professor, Department of Pharmacology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Karnataka, Manipal, 576104, India.
4Associate Professor, Department of Pathology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Karnataka, Manipal, 576104, India.
*Corresponding Author
Published In:
Volume - 17,
Issue - 5,
Year - 2024
ABSTRACT:
To determine nephroprotective activity of ubiquinol on ifosfamide induced renal damage by measuring the oxidative stress, biochemical parameters and histopathological examination. Thirty-six rats were divided into 6 groups, Group 1 rats were treated with 2ml of corn oil (vehicle) p.o., Group 2 and 3 received only ubiquinol of 10mg/kg/day and 50mg/kg/day respectively. Ubiquinol was prepared as oral suspensions with 2ml of corn oil. Group 4 received ifosfamide 80mg/kg/day, i.p. for 3 days. Groups 5 and 6 also received ubiquinol 10mg/kg/day and 50mg/kg/day respectively p.o. for 14 days. Then, we added ifosfamide to both the groups and dosed concomitantly along with ubiquinol from 8th -10th day. Ubiquinol proved to be an effective renoprotectant by decreasing the kidney to body weight ratio in ubiquinol treated IFO groups as compared to IFO group (p<0.05). Biochemical tests done on day 9 revealed that there was no significant difference in levels of Sr.Creatinine and total protein, but the levels of BUN were found to be significantly higher in IFO treated groups as compared to corn oil group (p<0.05). On day 15, it was seen that significant improvement in Sr.Creatinine, BUN and total protein levels of ubiquinol treated IFO groups as compared to IFO group (p<0.01). The levels of MDA and GSH were reversed in ubiquinol treated IFO groups as compared to IFO group (p<0.01). Histopathological examination supported that ubiquinol preserved the normal architecture of kidney in ubiquinol treated IFO groups. Ubiquinol proved to be an effective nephroprotective agent against ifosfamide induced nephrotoxicity.
Cite this article:
Vinayaka Anuhya, Amberkar Mohanbabu Vittalrao, Meena Kumari Kamalkishore*, Brij Mohan Kumar Singh, Gangaparameswari Soundarrajan. Evaluation of Nephroprotective effect of Ubiquinol on Ifosfamide Induced Nephrotoxicity in Albino Wistar Rats. Research Journal of Pharmacy and Technology. 2024; 17(5):2309-4. doi: 10.52711/0974-360X.2024.00362
Cite(Electronic):
Vinayaka Anuhya, Amberkar Mohanbabu Vittalrao, Meena Kumari Kamalkishore*, Brij Mohan Kumar Singh, Gangaparameswari Soundarrajan. Evaluation of Nephroprotective effect of Ubiquinol on Ifosfamide Induced Nephrotoxicity in Albino Wistar Rats. Research Journal of Pharmacy and Technology. 2024; 17(5):2309-4. doi: 10.52711/0974-360X.2024.00362 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-5-58
REFERENCES:
1. Fleming RA. An Overview of Cyclophosphamide and Ifosfamide Pharmacology. Pharmacotherapy 1997; 17(5Pt2): 146S–54S. PMID: 9322882.
2. Lafay-Cousin L, Mabbott DJ, Halliday W, Taylor MD, Tabori U, Kamaly-Asl ID et al. Use of ifosfamide, carboplatin, and etoposide chemotherapy in choroid plexus carcinoma. J Neurosurg Pediatr. 2010 ; 5(6): 615–21.doi: 10.3171/2010.3. PEDS09354.
3. Bonfante, Viviani, Santoro, Devizzi, Di Russo D, Zanini, et al. Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin’s disease. Br J Haematol. 1998; 103(2): 533–5. doi: 10.1046/j.1365-2141.1998.00989. x.
4. Springate J, Taub M. Ifosfamide toxicity in cultured proximal renal tubule cells. Pediatr Nephrol. 2007; 22(3): 358–65.doi: 10.1007/s00467-006-0328-7.
5. Singh AP, Muthuraman A, Jaggi AS, Singh N, Grover K, Dhawan R. Animal models of acute renal failure. Pharmacol Reports. 2012; 64(1): 31–44.doi: 10.1016/s1734-1140(12)70728-4.
6. Dechant KL, Brogden RN, Pilkington T, Faulds D. Ifosfamide/Mesna.A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs. 1991; 42(3): 428–67.doi: 10.2165/00003495-199142030-00006.
7. Brade WP, Herdrich K, Varini M. Ifosfamide-pharmacology, safety and therapeutic potential. Cancer Treat Rev. 1985; 12(1): 1–47. doi: 10.1016/0305-7372(85)90011-8
8. Smeitink J, Verreussel M, Schröder C, Lippens R. Nephrotoxicity associated with ifosfamide. European journal of pediatrics. 1988; 148(2): 164-6.https://doi.org/10.1007/BF00445929
9. Nissim I, Horyn O, Daikhin Y, Nissim I, Luhovyy B, Phillips PC, et al. Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer Res. 2006; 66(15): 7824–31.doi: 10.1158/0008-5472
10. Sarosy G. Ifosfamide--pharmacologic overview. Semin Oncol. 1989; 16(1 Suppl 3):2–8.PMID: 2649983.
11. Cui H, Kong Y, Zhang H. Oxidative stress, mitochondrial dysfunction, and aging. J Signal Transduct. 2012; 2012: 646354. doi: 10.1155/2012/646354.
12. Kawamukai M. Biosynthesis, bioproduction and novel roles of ubiquinone. J Biosci Bioeng. 2002; 94(6): 511–7. doi: 10.1016/s1389-1723(02)80188-8.
13. Singh U, Devaraj S, Jialal I. Coenzyme Q10 Supplementation and Heart Failure. Nutr Rev. 2008; 65(6pt1): 286–93.doi: 10.1301/nr.2007.jun.286-293.
14. Sandip Kumar Pahari, Somsubhra Ghosh, Srijita Halder, Mayukh Jana. Role of Coenzyme Q10 in human life. Research J. Pharm. and Tech. 2016; 9(6): 635-640.DOI: 10.5958/0974-360X.2016.00121.9
15. Hardevinder Pal Singh, Thakur Gurjeet Singh, Randhir Singh. Attenuation of Cisplatin–Induced Nephrotoxicity by p-Coumaric Acid through Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-γ) Agonism in male Rats. Research J. Pharm. and Tech. 2020; 13(11): 5270-5276
16. Ogbonnaya, E. Anthony, Monago, C. Comfort ,Belonwu, D. Chuka. Phytochemical Screening and Acute- and Organ- Toxicity Evaluation of Telfairia occidentalis Root Aqueous Extract on Normal Wister Rats. Research J. Pharmacognosy and Phytochemistry. 2010; 2(5): 417-420
17. Amruta V. Yadav, Mohd. Bashar Momin, Md. Awais Panjwani. Renoprotective effect of Corallocarpusepigaea in Nephropathy in Wistar Rats. Research J. Pharm. and Tech. 2020; 13(7): 3163-3168.
18. MK Kale, N Charbe, MP Patil, KP Bhusari. Theobroma Cocoa in Diabetic Nphrotoxicity. Research J. Pharm. and Tech. 2009; 2(2): 308-311
19. Vinodkumar Mugada, Jyothipriya Hanumanthu, Juhi Shagufa, Sosamma Iype, Sowmya Yerlapati. Assessment of Ototoxicity and Nephrotoxicity in patients receiving weekly Cisplatin Chemotherapy: A Prospective Observational Study. Research J. Pharm. and Tech. 2019; 12(4): 1922-1926
20. Seena K. X., M. Manjunath Setty. Protective effect of Phytochemicals against Cisplatin induced Nephrotoxicity. Research Journal of Pharmacy and Technology. 2021; 14(7): 3981-6.
21. Kim SY, Moon A. Drug-induced nephrotoxicity and its biomarkers. Biomol Ther (Seoul). 2012 ;20(3): 268–72.
22. Matés J.M. Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology. 2000; 153(1–3): 83–104